Tags

Type your tag names separated by a space and hit enter

A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome.
Dig Liver Dis. 2015 Feb; 47(2):119-24.DL

Abstract

BACKGROUND

We aimed to evaluate clinical symptoms in subjects with irritable bowel syndrome receiving Saccharomyces cerevisiae in a randomized double-blind placebo-controlled clinical trial.

METHODS

Overall, 179 adults with irritable bowel syndrome (Rome III criteria) were randomized to receive once daily 500 mg of Saccharomyces cerevisiae, delivered by one capsule (n = 86, F: 84%, age: 42.5 ± 12.5), or placebo (n = 93, F: 88%, age: 45.4 ± 14) for 8 weeks followed by a 3-week washout period. After a 2-week run-in period, cardinal symptoms (abdominal pain/discomfort, bloating/distension, bowel movement difficulty) and changes in stool frequency and consistency were recorded daily and assessed each week. A safety assessment was carried out throughout the study.

RESULTS

The proportion of responders, defined by an improvement of abdominal pain/discomfort, was significantly higher (p = 0.04) in the treated group than the placebo group (63% vs 47%, OR = 1.88, 95%, CI: 0.99-3.57) in the last 4 weeks of treatment. A non-significant trend of improvement was observed with Saccharomyces cerevisiae for the other symptoms. Saccharomyces cerevisiae was well tolerated and did not affect stool frequency and consistency.

CONCLUSION

Saccharomyces cerevisiae is well tolerated and reduces abdominal pain/discomfort scores without stool modification. Thus, Saccharomyces cerevisiae may be a new promising candidate for improving abdominal pain in subjects with irritable bowel syndrome.

Authors+Show Affiliations

CHU Lille, Department of Gastroenterology, Claude Huriez Hospital, Lille, France; Lille University North of France, Lille, France; INSERM U995, Lille, France.Lille University North of France, Lille, France; INSERM U995, Lille, France; Department of Microbiology, Faculty of Pharmacy, University of Lille, France.Lille University North of France, Lille, France; INSERM U995, Lille, France; CHU Lille, Department of Surgery, Claude Huriez Hospital, Lille, France.Biofortis-Mérieux NutriSciences, Nantes, France.Lesaffre International, Lesaffre Human Care, France.Lesaffre International, Lesaffre Human Care, France.CHU Lille, Department of Gastroenterology, Claude Huriez Hospital, Lille, France; Lille University North of France, Lille, France; INSERM U995, Lille, France. Electronic address: pdesreumaux@hotmail.com.

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

25488056

Citation

Pineton de Chambrun, Guillaume, et al. "A Randomized Clinical Trial of Saccharomyces Cerevisiae Versus Placebo in the Irritable Bowel Syndrome." Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 47, no. 2, 2015, pp. 119-24.
Pineton de Chambrun G, Neut C, Chau A, et al. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis. 2015;47(2):119-24.
Pineton de Chambrun, G., Neut, C., Chau, A., Cazaubiel, M., Pelerin, F., Justen, P., & Desreumaux, P. (2015). A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 47(2), 119-24. https://doi.org/10.1016/j.dld.2014.11.007
Pineton de Chambrun G, et al. A Randomized Clinical Trial of Saccharomyces Cerevisiae Versus Placebo in the Irritable Bowel Syndrome. Dig Liver Dis. 2015;47(2):119-24. PubMed PMID: 25488056.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. AU - Pineton de Chambrun,Guillaume, AU - Neut,Christel, AU - Chau,Amélie, AU - Cazaubiel,Murielle, AU - Pelerin,Fanny, AU - Justen,Peter, AU - Desreumaux,Pierre, Y1 - 2014/11/13/ PY - 2014/05/23/received PY - 2014/10/15/revised PY - 2014/11/04/accepted PY - 2014/12/10/entrez PY - 2014/12/10/pubmed PY - 2015/9/22/medline KW - Abdominal pain KW - Irritable bowel syndrome KW - Probiotic KW - Saccharomyces cerevisiae KW - Yeast SP - 119 EP - 24 JF - Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver JO - Dig Liver Dis VL - 47 IS - 2 N2 - BACKGROUND: We aimed to evaluate clinical symptoms in subjects with irritable bowel syndrome receiving Saccharomyces cerevisiae in a randomized double-blind placebo-controlled clinical trial. METHODS: Overall, 179 adults with irritable bowel syndrome (Rome III criteria) were randomized to receive once daily 500 mg of Saccharomyces cerevisiae, delivered by one capsule (n = 86, F: 84%, age: 42.5 ± 12.5), or placebo (n = 93, F: 88%, age: 45.4 ± 14) for 8 weeks followed by a 3-week washout period. After a 2-week run-in period, cardinal symptoms (abdominal pain/discomfort, bloating/distension, bowel movement difficulty) and changes in stool frequency and consistency were recorded daily and assessed each week. A safety assessment was carried out throughout the study. RESULTS: The proportion of responders, defined by an improvement of abdominal pain/discomfort, was significantly higher (p = 0.04) in the treated group than the placebo group (63% vs 47%, OR = 1.88, 95%, CI: 0.99-3.57) in the last 4 weeks of treatment. A non-significant trend of improvement was observed with Saccharomyces cerevisiae for the other symptoms. Saccharomyces cerevisiae was well tolerated and did not affect stool frequency and consistency. CONCLUSION: Saccharomyces cerevisiae is well tolerated and reduces abdominal pain/discomfort scores without stool modification. Thus, Saccharomyces cerevisiae may be a new promising candidate for improving abdominal pain in subjects with irritable bowel syndrome. SN - 1878-3562 UR - https://www.unboundmedicine.com/medline/citation/25488056/A_randomized_clinical_trial_of_Saccharomyces_cerevisiae_versus_placebo_in_the_irritable_bowel_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1590-8658(14)00792-0 DB - PRIME DP - Unbound Medicine ER -